Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
DAPAGLIFLOZIN FOR PREVENTION OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH TYPE TWO DIABETES: NUMBER NEEDED TO TREAT AND ASSOCIATED COSTS
Home
Publications
DAPAGLIFLOZIN FOR PREVENTION OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH TYPE TWO DIABETES: NUMBER NEEDED TO TREAT AND ASSOCIATED COSTS
DAPAGLIFLOZIN FOR PREVENTION OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH TYPE TWO DIABETES: NUMBER NEEDED TO TREAT AND ASSOCIATED COSTS
Authors:
RA
Ronen Arbel
Ronen Arbel
EA
Enis Aboalhasan
Enis Aboalhasan
AH
Ariel Hammerman
Ariel Hammerman
JA
Joseph Azuri
Joseph Azuri
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
1 May 2021
journal article
Published by
Elsevier
in
JACC
Vol. 77
(18)
,
335
DOI:
10.1016/s0735-1097(21)01694-6
Abstract
No abstract available
Keywords
DAPAGLIFLOZIN
Scroll to top